MedTrace Logo

Low Dose Naltrexone for Glioma Patients

NCT01303835 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2015-07-17

Study results available
· View outcomes & findings →

Summary

To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation

Conditions

  • Malignant Glioma

Interventions

DRUG

LDN

Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.

DRUG

Placebo

Randomized patients received placebo to be taken every night before bed.

Sponsors & Collaborators

  • Katy Peters

    lead OTHER

Principal Investigators

  • Katherine B Peters, MD, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-06-30
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01303835 on ClinicalTrials.gov